The immune response to tumour development is frequently targeted with therapeutics but remains largely unexplored in diagnostics. Here this groups designs an immunodiagnostic platform targeting amino acid residue biomarkers associated with tumour development and distinct from autoimmune and infectious diseases.
- Cong Tang
- Patrícia Corredeira
- Gonçalo J. L. Bernardes